Articles
12347 items
Taiho Ventures ups investments to $300M, to focus on oncology
Taiho Ventures LLC increased its investment pool to $300 million from $50 million. Taiho Ventures said it will focus the additional funds on oncology startups with drug discovery capabilities or unique platform technologies.
Taiho Pharmaceutical Co....
Biotech stocks ride tech rally
Biotech indexes ended the week on a positive note but it wasn’t enough to salvage the week.
The NASDAQ Biotechnology Index (NBI), SPDR S&P Biotech ETF (XBI), BioCentury 100 and NYSE Arca Biotechnology Index (BTK) each...
Iovance raises $219M for Phase II trials
Iovance Biotherapeutics (NASDAQ:IOVA) raised $219.3 million in a follow-on Friday to fund five ongoing company-sponsored Phase II trials of its tumor infiltrating lymphocyte (TIL) cell therapies and prepare for potential launch of its lead TIL...
Gene therapy company Audentes raises $151M
On the heels of data for one of its gene therapies, Audentes Therapeutics Inc. (NASDAQ:BOLD) raised $150.8 million Wednesday through the sale of 5.2 million shares at $29 in a follow-on underwritten by BofA Merrill...
First-day pop for Allogene after year's largest biotech IPO on NASDAQ
Less than a year after it was founded, cell therapy company Allogene Therapeutics Inc. (NASDAQ:ALLO) raised $324 million late Wednesday in the largest IPO by a biotech on NASDAQ thus far in 2018. The company...
Biotech slides with broader market
Biotech indexes fell Wednesday, mostly in line with the broader markets, marking significant mid-week losses. The moves come among continued trade tensions with China and follows the Federal Reserve raising interest rates for the third...
Versant-backed Gotham raises $54M series A
Versant Ventures unveiled a move into the RNA metabolism space with an investment in Gotham Therapeutics (New York, N.Y.). Versant co-led a $54 million series A round with Forbion Capital Partners and SR One.
Gotham is...
Polaris, Arch co-lead series A for MIT spinout Glympse
With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors...
Immunometabolism company Sitryx debuts with GSK ties, $30M
Sitryx Therapeutics Ltd. (Oxford, U.K.) emerged from stealth on Monday with $30 million from a series A round to develop disease-modifying therapeutics for immuno-oncology and immuno-inflammation, which CEO Neil Weir expects to be enough runway...
5AM looking for $350M sixth fund
5AM Ventures aims to raise $350 million for its sixth fund, according to an SEC filing.
The firm raised $285 million for its fifth fund, which closed in May 2016. 5AM led or co-led recent investments...
